Drug reprofiling strategy (or drug repositioining) is based upon the search for new therapeutical uses of already known drugs. The research starts with drugs that have already been approved from human use (Phase II onwards), thus avoiding the risks of development phases (preclinical and Phase I), which represent the main cause of failure in pharmaceutical development. The results of this research program with already known drugs are Phase II candidates and the time until market phase is also reduced.

Nowadays, about 50% of marketed drugs are new uses (new indications) of drugs that were originally approved to treat other diseases.
Neuron BioPharma employs the potential of its screening platforms of compounds with neuroprotective activity to scale-up this successful model through a systematic process to search from new indications in more than 1,000 drugs.